- ►bmj.com AI Adler, IM Stratton, HAW Neil, JS Yudkin, … - British Medical Journal, 2000 - bmj.com The UK prospective diabetes study (UKPDS) has shown that a policy of tight
control of blood pressure, which achieved a median blood pressure of 144/82 mm
Hg compared with 154/87 mm Hg over median 8.4 years of follow up, ... Cited by 930 - Related articles - BL Direct - All 21 versions
- ►diabetesjournals.org [PDF] MM Engelgau, KM Narayan, WH Herman - Diabetes Care, 2000 - Am Diabetes Assoc In 1997, nearly 16 million people in the US had diabetes (1,2). Of this
population, 10.3 million were diag- nosed and 5.4 million were undiagnosed
(1,2). In the future, these numbers are expected to increase substantially ... Cited by 221 - Related articles - All 9 versions
- ►annals.org [PDF] WH Herman, TJ Hoerger, M Brandle, K Hicks … - Annals of internal medicine, 2005 - Am Coll Physicians William H. Herman, MD, MPH; Thomas J. Hoerger, PhD; Michael Brandle, MD, MS;
Katherine Hicks, MS; Stephen Sorensen, PhD; Ping Zhang, PhD; Richard F. Hamman,
MD, DrPH; Ronald T. Ackermann, MD, MPH; Michael M. Engelgau, MD, MS; and ... Cited by 136 - Related articles - All 8 versions
[CITATION] National diabetes strategy and implementation plan
- ►oxfordjournals.org RA Rodby, RD Rohde, WR Clarke, LG … - Nephrology Dialysis Transplantation, 2000 - ERA-EDTA Background. Diabetic nephropathy is the most common cause of end-stage renal
disease in the developed world. Angiotensin-converting enzyme inhibitors have
been demonstrated to be renoprotective in type I diabetes and are now the ... Cited by 71 - Related articles - BL Direct - All 5 versions
- ►annals.org [PDF] AB Rosen, MB Hamel, MC Weinstein, DM … - Annals of Internal Medicine, 2005 - Am Coll Physicians Background: Angiotensin-converting enzyme (ACE) inhibitors slow renal disease
progression and reduce cardiac morbidity and mortality in patients with
diabetes. Patients' out-of-pocket costs pose a barrier to using this ... Cited by 70 - Related articles - BL Direct - All 12 versions
- Free from Publisher WH Herman, S Shahinfar, GW Carides, EJ … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—The Reduction of End Points in Type 2 Diabetes
With the Angiotensin II Antagonist Losartan (RENAAL) study was a multinational
double-blind randomized placebo-controlled clinical trial designed to ... Cited by 64 - Related articles - BL Direct - All 7 versions
SA Hood, JH Sondheimer - Semin Dial, 1998 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 41 - Related articles - BL Direct
- Free from Publisher AJ Palmer, L Annemans, S Roze, M Lamotte, P … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This study was a Markov model–simulated
progression from microalbuminuria to overt nephropathy, doubling of serum
creatinine, end-stage renal disease, and death in hypertensive patients ... Cited by 38 - Related articles - BL Direct - All 8 versions
A Gordois, P Scuffham, A Shearer, A Oglesby - Journal of Diabetes and its Complications, 2004 - Elsevier Problematic and debilitating complications result from diabetic nephropathy
(DN), which progresses during the course of diabetes. Up to 32% of people with
Type 2 diabetes have microalbuminuria; that is, a slight but clinically ... Cited by 37 - Related articles - All 13 versions
